Feasibility Testing an Exercise Program to Improve Cognition for T2DM Patients
Primary Purpose
Diabetes Mellitus, Type 2
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Supervised walking on a treadmill
Supervised stretching exercise
Sponsored by
About this trial
This is an interventional prevention trial for Diabetes Mellitus, Type 2 focused on measuring cognitive dysfunction, exercise
Eligibility Criteria
Inclusion Criteria:
- Participants eligible for this study will be sedentary adults with no major chronic physical or mental disorders but classified as having low physical activity levels determined by the International Physical Activity Questionnaire.
- Participants must have a documented medical diagnosis of T2DM and must be receiving diabetes care at the time of enrollment.
- Participants must be English-speaking and are able to give informed consent.
Exclusion Criteria:
- include uncontrolled hypertension with resting blood pressure of 160/90 mmHg or higher, having symptoms of coronary ischemia such as chest pain and severe shortness of breath during activities of daily living, loss of consciousness/fainting for any reason, or having any other medical or physical conditions (such as osteoporosis, asthma, spinal cord injury) or symptoms (e.g., pain or swelling in any part of the body) that may interfere with exercise participation.
Sites / Locations
- University of ArkansasRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Aerobic exercise group
Attention control group
Arm Description
Outcomes
Primary Outcome Measures
Episodic memory
Picture Sequence Memory Test. Test-retest reliability of the test is 0.77. Convergent validity and discriminant validity is 0.69 and -0.08, respectively.
Executive function
Dimensional Change Card Sort Test. Test-retest reliability of the test is 0.88. Convergent validity and discriminant validity is -0.51 and 0.14, respectively.
Working memory
List Sorting Working Memory Test. Test-retest reliability of the test is 0.77. Convergent validity and discriminant validity are 0.58 and 0.30, respectively.
Processing speed
Pattern Comparison Processing Speed Test. The test takes about 3 minutes to compete. Test-retest reliability of the test is 0.72. Convergent validity and discriminant validity is 0.49 and 0.12, respectively.
Secondary Outcome Measures
Plasma BDNF in ng/mL
BDNF in plasma will be measured using an ELISA kit.
Fasting blood glucose in mg/dL
Fasting blood glucose will be measured using YSI.
HbA1c in percentage
HbA1c will be measured using an ELISA kit.
Weight in kilograms
Weight will be measured with a health scale.
Height in meters
Height will be measured using a stadiometer.
BMI
weight and height will be combined to report BMI in kg/m^2
Full Information
NCT ID
NCT04590833
First Posted
October 9, 2020
Last Updated
January 7, 2022
Sponsor
University of Arkansas, Fayetteville
1. Study Identification
Unique Protocol Identification Number
NCT04590833
Brief Title
Feasibility Testing an Exercise Program to Improve Cognition for T2DM Patients
Official Title
Feasibility Testing a Randomized Controlled Trial of an Exercise Program to Improve Cognition for T2DM Patients
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2021 (Actual)
Primary Completion Date
September 24, 2023 (Anticipated)
Study Completion Date
September 24, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Arkansas, Fayetteville
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This proposed study will advance science by providing evidence on the feasibility of a standardized, rigorously designed and delivered exercise program to improve cognition and plasma brain-derived neurotrophic factor (BDNF) levels for individuals with type 2 diabetes. We will also explore how certain genetic variant may influence exercise-induced cognitive improvements and plasma BDNF levels. Findings of the proposed study will establish a comprehensive knowledge base for future research and development of a personalized exercise program for high-risk individuals who are vulnerable to cognitive dysfunction based on their genomic profiles.
Detailed Description
The study will pilot-test a 3-month supervised exercise program to improve plasma brain-derived neurotrophic factor (BDNF) levels and domains of cognition that are mostly affected in type 2 diabetes mellitus (T2DM), including memory, processing speed, and executive function, overall and according to genotypes of the BDNF Val66Met variant. T2DM impairs the brain, leading to cognitive dysfunction, which carries substantial lifetime consequences. This highlights an urgent need to find effective therapeutic strategies to improve cognitive function among those with T2DM. Aerobic exercise enhances cognitive function among healthy subjects through increased release of BDNF. BDNF supports survival of existing neurons and promotes growth of new neurons and synapses. Emerging evidence suggests that reduced BDNF levels may exacerbate cognitive dysfunction associated with T2DM. Compared to drug delivery of BDNF, aerobic exercise is a low- cost, safe, and easily accessible path to increasing endogenous BDNF levels. In persons with T2DM, integrity of the blood-brain barrier (BBB) is impaired. Although a growing body of evidence supports the protective role of regular exercise in BBB integrity, very little is known about how resting peripheral BDNF levels may change in response to regular aerobic exercise training after adjusting for BBB permeability among individuals with T2DM. One critical genetic variant that affects cognition in human is the BDNF Val66Met variant. The Met allele interferes with the activity-dependent secretion of mature BDNF among Met carriers. Despite the strong evidence suggesting aerobic exercise has a beneficial effect on cognitive function, significant variability in individual response to exercise training in cognitive outcomes has been reported among Val/Val vs. Met carriers. However, the evidence on how the BDNF Val66Met variant influences cognitive outcomes following an aerobic exercise intervention among individuals with T2DM is currently lacking. A total of 84 participants with T2DM will be randomized 2:1 to receive aerobic exercise intervention (n=56) or attention control (n=28) for 3 months. The study will evaluate the feasibility of the intervention. The study will also evaluate preliminary effectiveness of the supervised exercise program on cognitive function and plasma BDNF levels after controlling BBB permeability. An exploratory aim is to explore the influence of the BDNF Val66Met polymorphism on cognitive outcomes and plasma BDNF levels in response to aerobic exercise intervention. The purpose of this study is well aligned with the National Institute of Nursing Research (NINR) mission to develop personalized interventions that address mechanisms underlying symptoms of illness through symptom science research. Based on the findings of this proposed study, our long-term goal is to develop a personalized exercise program for high-risk individuals susceptible to cognitive dysfunction based on their genomic profiles.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
cognitive dysfunction, exercise
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
84 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Aerobic exercise group
Arm Type
Experimental
Arm Title
Attention control group
Arm Type
Placebo Comparator
Intervention Type
Behavioral
Intervention Name(s)
Supervised walking on a treadmill
Intervention Description
Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.
Intervention Type
Behavioral
Intervention Name(s)
Supervised stretching exercise
Intervention Description
Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
Primary Outcome Measure Information:
Title
Episodic memory
Description
Picture Sequence Memory Test. Test-retest reliability of the test is 0.77. Convergent validity and discriminant validity is 0.69 and -0.08, respectively.
Time Frame
Three months
Title
Executive function
Description
Dimensional Change Card Sort Test. Test-retest reliability of the test is 0.88. Convergent validity and discriminant validity is -0.51 and 0.14, respectively.
Time Frame
Three months
Title
Working memory
Description
List Sorting Working Memory Test. Test-retest reliability of the test is 0.77. Convergent validity and discriminant validity are 0.58 and 0.30, respectively.
Time Frame
Three months
Title
Processing speed
Description
Pattern Comparison Processing Speed Test. The test takes about 3 minutes to compete. Test-retest reliability of the test is 0.72. Convergent validity and discriminant validity is 0.49 and 0.12, respectively.
Time Frame
Three months
Secondary Outcome Measure Information:
Title
Plasma BDNF in ng/mL
Description
BDNF in plasma will be measured using an ELISA kit.
Time Frame
Three months
Title
Fasting blood glucose in mg/dL
Description
Fasting blood glucose will be measured using YSI.
Time Frame
Three months
Title
HbA1c in percentage
Description
HbA1c will be measured using an ELISA kit.
Time Frame
Three months
Title
Weight in kilograms
Description
Weight will be measured with a health scale.
Time Frame
Three months
Title
Height in meters
Description
Height will be measured using a stadiometer.
Time Frame
Three months
Title
BMI
Description
weight and height will be combined to report BMI in kg/m^2
Time Frame
Three months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participants eligible for this study will be sedentary adults with no major chronic physical or mental disorders but classified as having low physical activity levels determined by the International Physical Activity Questionnaire.
Participants must have a documented medical diagnosis of T2DM and must be receiving diabetes care at the time of enrollment.
Participants must be English-speaking and are able to give informed consent.
Exclusion Criteria:
include uncontrolled hypertension with resting blood pressure of 160/90 mmHg or higher, having symptoms of coronary ischemia such as chest pain and severe shortness of breath during activities of daily living, loss of consciousness/fainting for any reason, or having any other medical or physical conditions (such as osteoporosis, asthma, spinal cord injury) or symptoms (e.g., pain or swelling in any part of the body) that may interfere with exercise participation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tingting Liu, PhD
Phone
4795755038
Email
tl023@uark.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Wen-Juo Lo
Phone
(479) 575-6321
Email
wlo@uark.edu
Facility Information:
Facility Name
University of Arkansas
City
Fayetteville
State/Province
Arkansas
ZIP/Postal Code
72701
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tingting Liu, Ph.D.
Phone
479-575-5038
Email
tl023@uark.edu
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Feasibility Testing an Exercise Program to Improve Cognition for T2DM Patients
We'll reach out to this number within 24 hrs